Cited by 377Glioma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancerCancer, Hypoxia, and Metabolism

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

Chakravarti, Arnab, Zhai, Gary, Suzuki, Yoshiyuki, Sarkesh, Sormeh, Black, Peter M., Muzikansky, Alona, Loeffler, Jay S.·2004·Journal of Clinical Oncology

Abstract

Purpose The objectives of this study were to examine activation patterns of the phosphatidylinositol 3-kinase (PI3K) pathway in gliomas and to examine the prognostic significance of PI3K pathway activation using snap-frozen clinical specimens. Materials and methods Levels of expression of PI3K pathway members were assessed in 92 prospectively collected gliomas through quantitative Western analysis using total and phospho-specific antibodies for PI3K, Akt, and p70(s6k). Both expression and expression levels of these PI3K pathway members were correlated with histology, markers of apoptosis (cleaved caspase 3), and with clinical outcome (eg, overall survival). Results It was determined that activation of all three PI3K pathway members were significantly more frequent in glioblastoma multiforme than in non-glioblastoma multiforme tumors. Levels of phospho-PI3K, phospho-Akt, and phospho-p70(s6k) were all found to be inversely associated with cleaved caspase 3 levels, suggesting PI3K pathway activation is associated with reduced levels of apoptosis. Perhaps most importantly, activation of PI3K pathway members was found to be significantly associated with reduced survival times when all glioma cases were considered in aggregate. When glioblastoma cases were considered separately, the prognostic value of PI3K activation remained significant, suggesting that PI3K activation may directly be associated with radiation resistance, given that this was the only adjuvant therapy administered…

Integrity signals

Registry

Crossref · 10.1200/jco.2004.07.193

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PI3K signaling is hyperactivated in nearly 90% of GBMs, commonly as a consequence of EGFR amplification and activating mutation (EGFRvIII), and loss of the PTEN tumor suppressor protein.

    “PI3K signaling is hyperactivated in nearly 90% of GBMs, commonly as a consequence of EGFR amplification and activating mutation (EGFRvIII), and loss of the PTEN tumor suppressor protein, a negative regulator of PI3K signaling (6–8).”
  • PI3K signaling is hyperactivated as a consequence of RTK amplifications and activating mutations, PTEN loss, PI3K point mutations and other genetic lesions, providing a core oncogenic pathway in many cancers, including up to 90% of GBMs.

    “PI3K signaling is hyperactivated as a consequence of RTK amplifications and activating mutations, PTEN loss, PI3K point mutations and other genetic lesions, providing a core oncogenic pathway in many cancers, including up to 90% of GBMs (6, 8, 55).”

The citation lists haven’t been fetched yet

References 44 · Cited by 377

Authors
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S.
Affiliations
Brigham and Women's Hospital (US)
Venue
Journal of Clinical Oncology
Published
2004-05-15
Volume
22
Issue
10
Pages
1926-1933
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2125096000
Cited by
377
References
44
Citations by year
2026: 4 · 2025: 6 · 2024: 7 · 2023: 15 · 2022: 9 · 2021: 10 · 2020: 15 · 2019: 13 · 2018: 17 · 2017: 17 · 2016: 20 · 2015: 14 · 2014: 15 · 2013: 26 · 2012: 22
FWCI
12.68
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (K08CA082163, KO8CA82163)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
phosphatidylinositol 3-kinase pathway, glioma, glioblastoma, prognostic factors, Akt, p70S6K, apoptosis, cleaved caspase-3, overall survival, radioresistance (biology), tumor grade
MeSH terms
Glioma, Humans, Massachusetts, Neoplasm Staging, Predictive Value of Tests, Prospective Studies, Proto-Oncogene Proteins, Biomarkers, Tumor, Blotting, Western, Gene Expression Regulation, Neoplastic, Survival Analysis, Protein Serine-Threonine Kinases, Phosphatidylinositol 3-Kinases, Ribosomal Protein S6 Kinases, Proto-Oncogene Proteins c-akt

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review